View Financial HealthRange Impact 配当と自社株買い配当金 基準チェック /06Range Impact配当金を支払った記録がありません。主要情報n/a配当利回り-5.1%バイバック利回り総株主利回り-5.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Sep 25Range Impact, Inc. announced that it has received $0.55 million in funding from Tower Iv LLCRange Impact, Inc. entered into securities purchase agreements with Edward Feighan, the Chairman of the Board of Directors of the Company, Michael Cavanaugh, a director and Chief Executive Officer of the Company, and Tower IV, LLC, an existing shareholder of the Company on September 23, 2025. The company has issued 3,666,667 shares at a price of $0.15 per share for gross proceeds $550,000.05. Messrs. Feighan and Cavanaugh each invested $100,000 in the Shares and Tower IV, LLC invested $350,000. The transaction was closed on September 23, 2025.お知らせ • Oct 03Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE).Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024. A cash consideration will be paid by Placer Biosciences, Inc. As part of consideration, an undisclosed value is paid towards None of Graphium Biosciences, Inc. The consideration consists of (i) a warrant exchangeable into 1,000 shares of the common stock of the Purchaser, exercisable at $0.01 per share, expiring September 30, 2034, subject to certain anti-dilution adjustments; (ii) de minimis cash consideration; and (iii) 50% of any equipment sale proceeds realized by Purchaser during the 12-month period following the closing. The Stock Purchase Agreement contains terms, conditions, covenants, indemnification provisions, and representations and warranties from each of the respective parties that are customary and typical for a transaction of this nature. After a close review and examination of the status of both corporate strategies and the current market environment, the Company’s Board of Directors determined that it is in the shareholders’ best interests to separate these two distinct businesses by divesting Graphium. UB Greensfelder LLP acted as legal advisor to Range. Thompson Coburn LLP acted as legal advisor to Placer. Placer Biosciences, Inc. completed the acquisition of Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024.お知らせ • Jun 21Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million.Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million on June 17, 2024. A cash consideration valued at $0.27 per share will be paid by Continental Heritage Holding Company, Llc for the acquisition of 3,703,704 shares of the Company’s common stock. Continental Heritage Holding Company, Llc completed the acquisition of an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) on June 17, 2024.お知らせ • Apr 28+ 1 more updateRange Impact, Inc. Announces Chief Financial Officer ChangesRange Impact, Inc. (Range Impact) announced the transition of Richard McKilligan, Chief Financial Officer from Range Impact to Graphium Biosciences, Inc. (Graphium), a wholly owned subsidiary of Range Impact, in connection with a proposed divestiture and recapitalization of Graphium. Additionally, Range Impact has promoted Patricia Missal from her role as Corporate Controller to Chief Financial Officer. Mr. McKilligan joined the company in 2012 and held several management positions, including Controller, Counsel, and Chief Financial Officer. In connection with this expanded business strategy, all the company’s legacy drug development assets (for which Mr. McKilligan served in key leadership roles over the past decade) were transferred into Graphium in preparation for a future strategic transaction. Ms. Missal, age 55, has served as Controller of the Company since January 2023. Ms. Missal previously served as the Chief Financial Officer of Lux Global Label Company from August 2019 to February 2020, and then again from June 2021 to December 2022. She also served as Chief Financial Officer of Thirty-One Gifts, LLC from December 2019 to June 2021, and as Chief Financial Officer of Aero Communications, Inc. from September 2011 to June 2019. Ms. Missal, a CPA, received her BSBA in Accounting from Ashland University and her MBA from Cleveland State University.お知らせ • Dec 22Range Impact, Inc. announced that it has received $1.7 million in fundingRange Impact, Inc. announced that it has entered into securities purchase agreements with each of the purchasers to issue 11,333,336 shares at an issue price of $0.15 per share for the gross proceeds of $1,700,000.4 on December 21, 2023. The sale of the Shares was exempt from the registration requirements of the Securities Act as transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act (“Regulation D”). The Company made this determination based on the representations of the Purchasers in the Purchase Agreements, including, but not limited to, that each of them is an “accredited investor” within the meaning of Rule 501 of Regulation D and each of them had access to full and complete information about the Company and its investment.お知らせ • Sep 07Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million.Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million on August 31, 2023. The consideration comprised of $1.0 million of cash, a $2.0 million seller note collateralized by the acquired real estate and quarry infrastructure, and a separate $2.035 million seller note collateralized by the acquired equipment. Roger Collins will serve as Senior Vice President of Sales of Range Environmental Resources, Inc., a wholly-owned subsidiary of Malachite. Howard Groedel of Ulmer & Berne acted as legal advisor to Malachite Innovations, Inc. Thomas Spears of Daniels Law Firm, PLLC acted as legal advisor to Roger L. Collins, Jr. Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. on August 31, 2023.お知らせ • Aug 17Malachite Innovations, Inc. announced delayed 10-Q filingOn 08/16/2022, Malachite Innovations, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 21Vitality Biopharma, Inc. announced that it expects to receive $5 million in fundingVitality Biopharma, Inc. announced that it has entered into a securities purchase agreement with a institutional investor for private placement of common shares for gross proceeds of up to $5,000,000 on August 19, 2021. The company will issue shares in tranches of up to $250,000 until the financing arrangement expires on December 31, 2022. The share price is equal to 85% of the lowest daily volume weighted average price during the 5 trading days prior the 3rd business day following its submission of the purchase notice. The company will also issue warrants at a price equal to 115% of the lowest daily volume weighted average price expires on the five-year anniversary of the date of issuance.お知らせ • Sep 26Vitality Biopharma, Inc. Elects Brandon Zipp as Chief Science OfficerOn September 24, 2020, the Board of Directors of Vitality Biopharma, Inc. elected Dr. Brandon Zipp as Chief Science Officer.決済の安定と成長配当データの取得安定した配当: RNGEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RNGEの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Range Impact 配当利回り対市場RNGE 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RNGE)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Commercial Services)1.3%アナリスト予想 (RNGE) (最長3年)n/a注目すべき配当: RNGEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RNGEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RNGEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RNGEが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/06 13:51終値2026/05/06 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Range Impact, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Amit DayalH.C. Wainwright & Co.
お知らせ • Sep 25Range Impact, Inc. announced that it has received $0.55 million in funding from Tower Iv LLCRange Impact, Inc. entered into securities purchase agreements with Edward Feighan, the Chairman of the Board of Directors of the Company, Michael Cavanaugh, a director and Chief Executive Officer of the Company, and Tower IV, LLC, an existing shareholder of the Company on September 23, 2025. The company has issued 3,666,667 shares at a price of $0.15 per share for gross proceeds $550,000.05. Messrs. Feighan and Cavanaugh each invested $100,000 in the Shares and Tower IV, LLC invested $350,000. The transaction was closed on September 23, 2025.
お知らせ • Oct 03Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE).Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024. A cash consideration will be paid by Placer Biosciences, Inc. As part of consideration, an undisclosed value is paid towards None of Graphium Biosciences, Inc. The consideration consists of (i) a warrant exchangeable into 1,000 shares of the common stock of the Purchaser, exercisable at $0.01 per share, expiring September 30, 2034, subject to certain anti-dilution adjustments; (ii) de minimis cash consideration; and (iii) 50% of any equipment sale proceeds realized by Purchaser during the 12-month period following the closing. The Stock Purchase Agreement contains terms, conditions, covenants, indemnification provisions, and representations and warranties from each of the respective parties that are customary and typical for a transaction of this nature. After a close review and examination of the status of both corporate strategies and the current market environment, the Company’s Board of Directors determined that it is in the shareholders’ best interests to separate these two distinct businesses by divesting Graphium. UB Greensfelder LLP acted as legal advisor to Range. Thompson Coburn LLP acted as legal advisor to Placer. Placer Biosciences, Inc. completed the acquisition of Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024.
お知らせ • Jun 21Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million.Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million on June 17, 2024. A cash consideration valued at $0.27 per share will be paid by Continental Heritage Holding Company, Llc for the acquisition of 3,703,704 shares of the Company’s common stock. Continental Heritage Holding Company, Llc completed the acquisition of an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) on June 17, 2024.
お知らせ • Apr 28+ 1 more updateRange Impact, Inc. Announces Chief Financial Officer ChangesRange Impact, Inc. (Range Impact) announced the transition of Richard McKilligan, Chief Financial Officer from Range Impact to Graphium Biosciences, Inc. (Graphium), a wholly owned subsidiary of Range Impact, in connection with a proposed divestiture and recapitalization of Graphium. Additionally, Range Impact has promoted Patricia Missal from her role as Corporate Controller to Chief Financial Officer. Mr. McKilligan joined the company in 2012 and held several management positions, including Controller, Counsel, and Chief Financial Officer. In connection with this expanded business strategy, all the company’s legacy drug development assets (for which Mr. McKilligan served in key leadership roles over the past decade) were transferred into Graphium in preparation for a future strategic transaction. Ms. Missal, age 55, has served as Controller of the Company since January 2023. Ms. Missal previously served as the Chief Financial Officer of Lux Global Label Company from August 2019 to February 2020, and then again from June 2021 to December 2022. She also served as Chief Financial Officer of Thirty-One Gifts, LLC from December 2019 to June 2021, and as Chief Financial Officer of Aero Communications, Inc. from September 2011 to June 2019. Ms. Missal, a CPA, received her BSBA in Accounting from Ashland University and her MBA from Cleveland State University.
お知らせ • Dec 22Range Impact, Inc. announced that it has received $1.7 million in fundingRange Impact, Inc. announced that it has entered into securities purchase agreements with each of the purchasers to issue 11,333,336 shares at an issue price of $0.15 per share for the gross proceeds of $1,700,000.4 on December 21, 2023. The sale of the Shares was exempt from the registration requirements of the Securities Act as transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act (“Regulation D”). The Company made this determination based on the representations of the Purchasers in the Purchase Agreements, including, but not limited to, that each of them is an “accredited investor” within the meaning of Rule 501 of Regulation D and each of them had access to full and complete information about the Company and its investment.
お知らせ • Sep 07Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million.Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million on August 31, 2023. The consideration comprised of $1.0 million of cash, a $2.0 million seller note collateralized by the acquired real estate and quarry infrastructure, and a separate $2.035 million seller note collateralized by the acquired equipment. Roger Collins will serve as Senior Vice President of Sales of Range Environmental Resources, Inc., a wholly-owned subsidiary of Malachite. Howard Groedel of Ulmer & Berne acted as legal advisor to Malachite Innovations, Inc. Thomas Spears of Daniels Law Firm, PLLC acted as legal advisor to Roger L. Collins, Jr. Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. on August 31, 2023.
お知らせ • Aug 17Malachite Innovations, Inc. announced delayed 10-Q filingOn 08/16/2022, Malachite Innovations, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 21Vitality Biopharma, Inc. announced that it expects to receive $5 million in fundingVitality Biopharma, Inc. announced that it has entered into a securities purchase agreement with a institutional investor for private placement of common shares for gross proceeds of up to $5,000,000 on August 19, 2021. The company will issue shares in tranches of up to $250,000 until the financing arrangement expires on December 31, 2022. The share price is equal to 85% of the lowest daily volume weighted average price during the 5 trading days prior the 3rd business day following its submission of the purchase notice. The company will also issue warrants at a price equal to 115% of the lowest daily volume weighted average price expires on the five-year anniversary of the date of issuance.
お知らせ • Sep 26Vitality Biopharma, Inc. Elects Brandon Zipp as Chief Science OfficerOn September 24, 2020, the Board of Directors of Vitality Biopharma, Inc. elected Dr. Brandon Zipp as Chief Science Officer.